Accueil   Diary - News   All news POXEL and ENYO Pharma sign license agreement for POXEL’s FXR Agonist Program

POXEL and ENYO Pharma sign license agreement for POXEL’s FXR Agonist Program

POXEL SA, a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, and ENYO Pharma SAS, a newly-formed company focused on the treatment of acute and chronic viral infections, today announced the signing of a license agreement under which ENYO will gain access to Poxel’s FXR (farnesoid X receptor) agonist compounds for infection-related indications with Poxel retaining rights for cardiovascular and metabolic indications among others. No financial terms of the agreement have been disclosed.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree